. 2021 Jan 5;20:199–208. doi: 10.1016/j.omto.2020.12.013

Table 2.

Stratification analysis between WTAP genotypes and glioma risk

Variables	rs7766006 (cases/controls)		AOR (95% CI)^a	p^a	Risk genotypes^b (cases/controls)		AOR (95% CI)^a	p^a
	GG	GT/TT			0–2	3

Age, months

<60	27/40	58/79	1.09 (0.60–1.98)	0.775	27/40	58/79	1.09 (0.60–1.98)	0.775
≥60	30/57	56/52	2.10 (1.17–3.78)^c	0.013^c	30/57	56/52	2.10 (1.17–3.78)^c	0.013^c

Gender

Females	30/40	51/53	1.39 (0.75–2.60)	0.300	30/40	51/53	1.39 (0.75–2.60)	0.300
Males	27/57	63/78	1.76 (1.00–3.12)	0.052	27/57	63/78	1.76 (1.00–3.12)	0.052

Subtypes

Astrocytic tumors	43/97	82/131	1.54 (0.96–2.45)	0.071	43/97	82/131	1.54 (0.96–2.45)	0.071
Ependymoma	10/97	15/131	0.98 (0.42–2.32)	0.971	10/97	15/131	0.98 (0.42–2.32)	0.971
Neuronal and mixed	3/97	11/131	2.48 (0.66–9.24)	0.177	3/97	11/131	2.48 (0.66–9.24)	0.177
Embryonal tumors	1/97	6/131	17.00 (1.03–281.79)^c	0.048^c	1/97^c	6/131^c	17.00 (1.03–281.79)^c	0.048^c

Tumor grades

I	31/97	72/131	1.86 (1.12–3.08)	0.017	31/97	72/131	1.86 (1.12–3.08)	0.017
II	12/97	16/131	0.98 (0.44–2.19)	0.964	12/97	16/131	0.98 (0.44–2.19)	0.964
III	5/97	10/131	1.31 (0.43–4.02)	0.632	5/97	10/131	1.31 (0.43–4.02)	0.632
IV	9/97	16/131	1.71 (0.67–4.33)	0.259	9/97	16/131	1.71 (0.67–4.33)	0.259
I+II	43/97	88/131	1.61 (1.02–2.54)^c	0.041^c	43/97	88/131	1.61 (1.02–2.54)^c	0.041^c
III+IV	14/97	26/131	1.56 (0.76–3.22)	0.226	14/97	26/131	1.56 (0.76–3.22)	0.226

AOR, adjusted odds ratio; CI, confidence interval.

Adjusted for age and gender, omitting the corresponding stratify factor.

Risk genotypes were carriers with rs9457712 GG/GA, rs1853259 AA/AG, and rs7766006 GT/TT genotypes.

Significant results.